A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer

Inclusion Criteria:

- Advanced colorectal carcinoma.

- Progression on prior oxaliplatin-containing regimen used in 1st line setting for mCRC
or progression within 6 months of end of oxaliplatin-containing regimen in the
adjuvant setting.

- Tumor tissue available at time of screening for molecular profiling.

- Adequate performance status.

- Adequate glucose control, bone marrow, kidney, liver, and heart function.

Exclusion Criteria:

- Participation in other studies involving investigational drug(s) (Phases 1-4) before
the current study begins and/or during study participation.

- Prior irinotecan treatment.

- Prior radiation to the pelvis or abdomen in the metastatic or locally advanced
setting.

- History of Gilbert's syndrome.

- Active brain metastases.

- Deep vein thrombosis in the preceding 2 months.

- History of interstitial lung disease.

- RAS (KRAS/NRAS) wild type mCRC not previously treated with an anti-EGFR containing
regimen (unless contraindicated or not considered standard practice per clinical site
or country guidelines).